Gene shut-down may offer early warning of chronic leukemia
August 5, 2009A new study shows that certain genes are turned off early, before clinical signs of the disease appear, in the development of chronic leukemia.
The study, led by researchers at the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, examined cancer cells from patients with chronic lymphocytic leukemia (CLL) and from a new strain of mice that develops a very similar disease.
The findings suggest that changes called epigenetic alterations, which silence a gene's ability to make its protein, might serve as markers for detecting CLL early and for monitoring its progression. They also point to a strategy for treating the disease earlier using drugs that reverse such changes, and further confirm the value of the mouse model for studying CLL causes and treatment, researchers say.
The research revealed that a gene called FOXD3 likely plays a key role in CLL, and that the gene is silenced early, followed by the silencing of other genes.
The findings are published online in the Proceedings of the National Academy of Sciences Early Edition.
"Our data suggest that the silencing of FOXD3 might represent a very early gene involved in the initiation of CLL that we can potentially target for re-expression with specific drugs," says study leader Dr. John C. Byrd, professor of internal medicine, director of the hematologic malignancies program at the James Cancer Hospital and Solove Research Institute and a CLL specialist. "Next, we need to learn whether therapy to reverse this silencing can delay or prevent CLL progression."
An estimated 15,500 Americans are expected to develop CLL in 2009, and about 4,400 people will die of the disease. The malignancy usually strikes people aged 50 or older, causing white blood cells called B lymphocytes to proliferate. This can lead to severe anemia and dangerous viral, bacterial and fungal infections. Average survival is eight to 12 years from diagnosis.
The animal model, called the TCL1 transgenic mouse, was developed by Ohio State cancer researcher Dr. Carlo M. Croce and a group of colleagues in 2002. An earlier study by Byrd and his laboratory showed that the disease in the mouse has many of the same molecular and genetic features as human CLL, responds to drugs used to treat the disease and develops drug resistance, as CLL patients often do.
"Data from this new study demonstrate a strong similarity in gene silencing patterns in the mouse leukemia and in human CLL, suggesting that the changes in the mice mimic critical changes in different stages of the human disease," says Byrd, who worked closely on the study with first author and graduate student Shih-Shih Chen, co-senior author Christoph Plass at the German Cancer Research Center in Heidelberg, and other colleagues.
"We know that human CLL involves the silencing of a number of genes, but we can look at human CLL only after patients develop the disease," he says.
"This mouse model now allows us to look at events leading up to the disease and perhaps identify markers for early disease detection and the testing of new therapies."
Source: Ohio State University Medical Center
-
Breed of mice created for leukemia study
Aug 22, 2006 |
not rated yet |
0
-
Knocking Out Survival Protein Could Aid Leukemia Treatment
Apr 23, 2007 |
not rated yet |
0
-
'Modular' Leukemia Drug Shows Promise In Early Testing
Jun 29, 2007 |
not rated yet |
0
-
Researchers discover inherited mutation for leukemia
May 31, 2007 |
not rated yet |
0
-
Two suppressor molecules affect 70 genes in leukemia
Apr 24, 2008 |
not rated yet |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (31) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (3) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (1) |
0
-
We the immaterial soul
3 hours ago
-
Is Everyday Technology Killing Us?
Feb 08, 2012
-
Exercise and weight loss
Feb 08, 2012
-
Why do we have head aches? Our brains can't feel anything.
Feb 07, 2012
-
"The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
Feb 04, 2012
-
Oncolytic adenovirus
Feb 04, 2012
- More from Physics Forums - Medical Sciences
More news stories
Study finds that anti-diabetic medication can prevent the long-term effects of maternal obesity
In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication ...
21 hours ago |
5 / 5 (1) |
1
FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice
Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, show t ...
Medicine & Health / Neuroscience
Feb 09, 2012 |
4.9 / 5 (52) |
20
|
Teen school drop-outs three times as likely to be on benefits in later life
Teen school drop-outs are almost three times as likely to be on benefits in later life as their peers who complete their schooling, indicates research published online in the Journal of Epidemiology and Community Health.
Feb 06, 2012 |
not rated yet |
11
Amateur football players not always keen on returning to play after ACL injuries
Despite the known success rates of reconstructive Anterior Cruciate Ligament (ACL) surgery, the number of high school and collegiate football players returning to play may not be as high as anticipated, say researchers presenting ...
21 hours ago |
not rated yet |
0
Steroid injections prove effective in treatment of lumbar disc herniations
The use of epidural steroid injections may be a more efficient treatment option for lumbar disc herniations, according to research presented today at the American Orthopaedic Society for Sports Medicine's Specialty Day in ...
21 hours ago |
5 / 5 (1) |
0
Google might launch Drive for cloud storage soon
(PhysOrg.com) -- Google's next big move, according to the Wall Street Journal, is a cloud storage service called Drive. Hardly first to the plate, Google is simply catching up to introducing its cloud reposi ...
Latin America mining boom clashes with conservation
Latin America is experiencing a mining boom as prices rise fuelled by a hike in global demand, but the region is also being hit by a wave of violent protests, strikes and rallies by environmentalists.
Love a click away in Indonesia's Twitter Republic
He was a geeky kid from Yogyakarta, she a glamorous city girl in Jakarta. In a country with one of the world's most vibrant social networking scenes they fell in love on Twitter.
Walney offshore wind farm is world's biggest (for now)
(PhysOrg.com) -- The Walney wind farm on the Irish Sea--characterized by high tides, waves and windy weather--officially opened this week. The farm is treated in the press as a very big deal as the Walney ...
GPS court ruling leaves US phone tracking unclear
A US Supreme Court decision requiring a warrant to place a GPS device on the car of a criminal suspect leaves unresolved the bigger issue of police tracking using mobile phones, legal experts say.
Europeans protest controversial Internet pact
Tens of thousands of people marched in protests in more than a dozen European cities Saturday against a controversial anti-online piracy pact that critics say could curtail Internet freedom.